BioCentury
ARTICLE | Company News

Biogen opts in for Ionis' ALS candidate, plans pivotal trial

December 6, 2018 8:23 PM UTC

Biogen Inc. (NASDAQ:BIIB) exercised its option for exclusive, worldwide rights to BIIB067 (IONIS-SOD1Rx) from Ionis Pharmaceuticals Inc. (NASDAQ:IONS) to treat amyotrophic lateral sclerosis with superoxide dismutase 1 (SOD1) mutations.

Biogen, which opted in after seeing interim Phase I data, plans to begin a pivotal trial of the SOD1-inhibiting antisense oligonucleotide. Biogen declined to give a timeline...